TY - JOUR T1 - Echocardiographic features of left ventricular dysfunction and outcomes in chronic kidney disease JF - Heart JO - Heart DO - 10.1136/heartjnl-2022-321404 SP - heartjnl-2022-321404 AU - Shuo-Ming Ou AU - Chieh-Ju Chao AU - Ming-Tsun Tsai AU - Kuo-Hua Lee AU - Wei-Cheng Tseng AU - Pin-Jie Bin AU - Yao-Ping Lin AU - Chien-Yi Hsu AU - Der-Cherng Tarng Y1 - 2022/08/29 UR - http://heart.bmj.com/content/early/2022/08/28/heartjnl-2022-321404.abstract N2 - Objective Heart failure (HF) imposes a substantial burden and the prevalence of HF is high in patients with chronic kidney disease (CKD). HF results in multiple hospital admissions, but whether HF subtypes worsen long-term outcomes and renal function in patients with CKD remains inconclusive.Methods The study comprised 10 904 patients with CKD aged ≥20 years who underwent echocardiography between 1 January 2011 and 31 December 2018. The patients were stratified into four groups: non-HF, HF with reduced ejection fraction (HFrEF), HF with mildly reduced ejection fraction (HFmrEF) and HF with preserved ejection fraction (HFpEF). The primary end points were all-cause mortality, major adverse cardiovascular events (MACEs) and adverse renal outcomes.Results In inverse probability of treatment weighting-adjusted method, the risk of all-cause mortality and MACEs relative to the non-HF group was greatest in the HFrEF group (HR 3.18 (95% CI 2.57 to 3.93) and HR 3.83 (95% CI 3.20 to 4.59)), followed by the HFmrEF (HR 2.75 (95% CI 2.22 to 3.42) and HR 3.08 (95% CI 2.57 to 3.69)) and HFpEF (HR 1.85 (95% CI 1.59 to 2.15) and HR 2.43 (95% CI 2.16 to 2.73) groups. In addition, the HFrEF group had the greatest risks of end-stage renal disease (HR 2.58 (95% CI 1.94 to 3.44)) compared with other groups.Conclusions HF is associated with subsequent worse clinical outcomes, which may be more pronounced in patients with HFrEF, followed by those with HFmrEF and those with HFpEF relative to non-HF group.Data are available on reasonable request. ER -